- Home
- PNI vs BOLD Comparison
PNI vs BOLD Comparison
Compare PNI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PNI | BOLD |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.8M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | PNI | BOLD |
|---|---|---|
| Price | $6.83 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 26.4K | ★ 185.6K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.03 | $1.00 |
| 52 Week High | $7.89 | $3.45 |
Technical Indicators
Market Signals| Indicator | PNI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.10 | 43.90 |
| Support Level | $6.86 | $1.11 |
| Resistance Level | $6.97 | $1.20 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.62 | 65.00 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.